Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide

Int J STD AIDS. 2020 Mar;31(4):380-382. doi: 10.1177/0956462419895665. Epub 2020 Feb 10.
No abstract available

Keywords: AIDS; Bictegravir; HIV; antiretroviral; gynecomastia; highly active antiretroviral therapy; integrase inhibitor; integrase strand transfer inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Adenine / adverse effects
  • Adenine / analogs & derivatives
  • Adenine / therapeutic use
  • Adult
  • Alanine
  • Amides
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Antiretroviral Therapy, Highly Active / methods
  • CD4 Lymphocyte Count
  • Drug Combinations
  • Emtricitabine / adverse effects
  • Emtricitabine / therapeutic use
  • Gynecomastia / chemically induced*
  • Gynecomastia / diagnostic imaging
  • HIV Infections / drug therapy*
  • HIV-1 / drug effects*
  • Heterocyclic Compounds, 3-Ring
  • Heterocyclic Compounds, 4 or More Rings / adverse effects
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use
  • Humans
  • Male
  • Piperazines
  • Pyridones
  • Tenofovir / analogs & derivatives
  • Treatment Outcome

Substances

  • Amides
  • Anti-HIV Agents
  • Drug Combinations
  • Heterocyclic Compounds, 3-Ring
  • Heterocyclic Compounds, 4 or More Rings
  • Piperazines
  • Pyridones
  • bictegravir
  • Tenofovir
  • tenofovir alafenamide
  • Emtricitabine
  • Adenine
  • Alanine